ECP 2018 Final Programme

TRK, tropomyosin receptorkinase. References:1 .OkimotoRA,BivonaTG.Trackingdown responseand resistance toTRK inhibitors. CancerDiscov .2016;6(1):14-16. 2 .VaishnaviA,LeAT,DoebeleRC.TRKingdownanoldoncogene inaneweraof targeted therapy. CancerDiscov .2015;5(1):25-34. © 2018 Bayer and Loxo Oncology, Inc. All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer. PP-LAR-ALL-0001 06/2018 L.ES.MKT.05.2018.4374 THERE’S MORE TO SOME CANCERS THAN MEETS THE EYE LOOK BELOW THE SURFACE TO FIND OUT WHAT’S DRIVING THE TUMOR TRK FUSION PROTEINS ARE A PRIMARY ONCOGENIC DRIVER ACROSS MULTIPLE TUMORS IN ADULTS AND CHILDREN 1,2 LEARN MORE ABOUT TRK FUSION CANCER AT TRKCANCER.COM